glaxosmithkline plc-spon adr (GSK) Key Developments
GSK Invests in Antibiotic Manufacturing Facility in Singapore
Jun 25 15
GlaxoSmithKline plans to invest another GBP 38 million into its antibiotic manufacturing plant in Singapore. The increase in investment comes in addition to GSK's original investment of SGD 60 million in 2012. GSK expects the latest investment to boost the plant's production by 50%.
GlaxoSmithKline Updates on BEXSERO
Jun 24 15
GlaxoSmithKline announced that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO® (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18). This recommendation means that the decision to vaccinate against meningococcal group B will be made by qualified healthcare professionals, based on individual patient risk assessment. BEXSERO® was approved by the U.S. Food and Drug Administration (FDA) in January 2015 through an accelerated approval pathway for use in individuals aged 10 through 25 years and acquired by GSK in March 2015 following the closure of the three-part transaction with Novartis. During meeting on June 24, 2015, the ACIP also voted to include BEXSERO® in the CDC's Vaccines for Children (VFC) program for ages 16 through 18. The ACIP voted in February for the use of meningococcal group B vaccines in people greater than 10 years of age at increased risk for meningococcal group B disease and this was published on June 12, 2015. GSK is evaluating the safety and immune response of a pentavalent meningococcal vaccine (A, C, W-135, Y, plus B) which is now in Phase 2 research. GSK plans to continue to invest in vaccines against this disease as a key part of its growth strategy.
GlaxoSmithKline (UK) Announces Launch of US-Based Altius Institute for Biomedical Sciences; Appoints John A Stamatoyannopoulos to Lead the Altius Institute for Biomedical Sciences
Jun 22 15
GlaxoSmithKline (UK) has announced the launch of an independent non-profit research institute - the Altius Institute for Biomedical Sciences - based in Seattle, Washington. GSK signed a 10-year research agreement with Altius, whereby the firm will contribute more than USD 95 million in the first five years to help fund research activities that are also anticipated to receive funding from public and other sources. Furthermore, undisclosed additional funding will be provided by GSK for certain drug discovery and development projects selected by the firm.
The institute will be led by John A Stamatoyannopoulos, professor of Genome Sciences and Medicine at the University of Washington School of Medicine, and will be focused on developing new technologies for identification of genes involved in controlling a cell's operating functions during the states of health and disease. Altius is anticipated to become operational later in 2015.
GlaxoSmithKline Announces Executive Changes
Jun 22 15
GlaxoSmithKline has named Annaswamy Vaidheesh as its new vice president for South Asia division and managing director of the firm. Vaidheesh would succeed current managing director Hasit Joshipura, who is expected to be appointed on a new role in the company. Prior to his new role, Vaidheesh was working as vice president of corporate government affairs at Johnson & Johnson Asia-Pacific headquartered in Singapore. He also served as managing director at Johnson & Johnson Medical India and also remained vice president at Diabetes' Asia-Pacific franchise in Mumbai.
Glaxosmithkline Sells Meningitis Vaccines to Pfizer
Jun 22 15
GlaxoSmthKline plc plans to sell meningitis vaccines Nimenrix and Mencevaz to Pfizer Inc. (PFE) for EUR 115 million. The divestment addresses commitments GlaxoSmithKline made to regulators at the European Commission and elsewhere in connection with its three-pronged transaction with Novartis AG, which closed in March. The deal included the EUR 5.25 billion purchase of most of Novartis' vaccines unit, including meningitis products Menveo and Bexsero, as well as the formation of a consumer healthcare joint venture and the EUR 16 billion sale to Novartis of GlaxoSmithKline's oncology division. The two vaccines the U.K. company is selling to Pfizer are available outside the U.S. They had sales in 2014 of EUR 34 million. The EC and other regulators need to clear the deal, which counts as a related-party transaction since Pfizer is GlaxoSmithKline's partner in the ViiV Healthcare Ltd. HIV drugs venture. A Ropes & Gray LLP team led by Christopher Comeau and Mark Bellomy provided legal counsel to Pfizer.